CEL-SCI Corporation held its annual shareholder meeting on August 14, 2026, where shareholders elected three directors for the upcoming year. Geert Kersten received 4,371,909 votes for and 478,675 withheld; Bruno Baillavoine received 2,188,254 for and 2,662,330 withheld; Robert Watson received 2,062,150 for and 2,788,434 withheld, with 4,365,596 broker non-votes for each director.
Shareholders approved CEL-SCI’s 2026 Non-Qualified Stock Option Plan, 2026 Stock Bonus Plan, a non-binding advisory vote on executive compensation, and ratified BDO USA, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026. For these proposals, votes for ranged from 3,654,395 to 8,638,163. On the advisory vote regarding the frequency of say-on-pay, shareholders cast 1,692,789 votes for one year, 158,296 for two years, and 2,668,661 for three years, with 330,838 abstentions.
CEL-SCI Corporation reported continued operating losses and tight liquidity for the nine months ended June 30, 2026 while advancing its cancer immunotherapy program Multikine toward a planned confirmatory Phase 3 registration study. The company generated no revenue and recorded a net loss of $16.6 million, modestly improved from $19.3 million a year earlier, driven by lower research and development and general and administrative expenses.
Total assets declined to $21.4 million from $28.2 million, with cash and cash equivalents falling to $6.5 million from $11.0 million. Net cash used in operating activities was $12.1 million, partly offset by $9.7 million of equity financing proceeds and officer purchases, resulting in a $4.4 million cash decrease. Stockholders’ equity fell to $11.0 million from $16.0 million, and the accumulated deficit widened to $556.0 million.
Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and future liquidity needs. To fund a 212‑patient Multikine confirmatory registration study, the cost is estimated at $30–$35 million, and additional financing through partnerships, debt, or equity will be required.
CEL-SCI Corporation has called its 2026 annual shareholder meeting for August 14, 2026 in Vienna, Virginia. Shareholders will elect directors, vote on a new 2026 Non-Qualified Stock Option Plan covering up to 2,600,000 shares, and a 2026 Stock Bonus Plan covering up to 400,000 shares.
They will also cast non-binding advisory votes on executive compensation and how often to hold future say-on-pay votes, with the Board recommending every three years, and will vote on ratifying BDO USA, P.C. as independent auditor for the fiscal year ending September 30, 2026. CEL-SCI reports 17,477,144 common shares outstanding as of June 18, 2026 and discloses detailed executive pay, including 2025 CEO total compensation of $919,854.
TALOR EYAL reported acquisition or exercise transactions in this Form 4 filing.
CEL SCI CORP Chief Scientific Officer receives stock grant. Chief Scientific Officer Talor Eyal was granted 2,307 shares of CEL SCI CORP common stock at a reference price of $1.04 per share. After this compensation-related award, Eyal directly holds a total of 9,318 common shares.
CEL SCI CORP Chief Financial Officer Patricia B. Prichep received a grant or award of 4,125 shares of common stock on June 30, 2026 at a reported value of $1.04 per share. After this acquisition, she directly owns 17,489 shares of the company’s common stock.
CEL-SCI Corp Chief Executive Officer Geert R. Kersten reported a compensation-related acquisition of 5,192 shares of common stock at $1.04 per share. Following this grant, he directly holds 216,142 common shares and indirectly holds 311,547 common shares as trustee.
CEL-SCI Corporation has priced a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, for expected gross proceeds of $2.5 million before fees and expenses. The offering is expected to close on June 16, 2026, subject to customary conditions.
The company plans to use the cash to continue developing its investigational cancer immunotherapy Multikine, as well as for general corporate purposes and working capital. The shares are being sold under an effective Form S-3 shelf registration, with ThinkEquity acting as sole placement agent.
CEL-SCI Corporation is offering 2,500,000 shares of common stock at $1.00 per share on a best-efforts basis. The offering is expected to deliver gross proceeds of $2,500,000 and estimated net proceeds of approximately $2.2 million to fund continued development of Multikine and for general corporate purposes. The prospectus supplement notes there is no minimum offering requirement, placement agent fees of $0.07 per share, and that closing is expected on or about June 16, 2026. The company reported 14,977,144 shares outstanding prior to this offering (as of June 12, 2026), and anticipates 17,477,144 shares outstanding after this offering.